EP Patent

EP1965828A2 — Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide

Assigned to Amylin Pharmaceuticals LLC · Expires 2008-09-10 · 18y expired

What this patent protects

What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.

USPTO Abstract

What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
EP1965828A2
Jurisdiction
EP
Classification
—
Expires
2008-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Amylin Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.